These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 8123940)
1. Toremifene enhances cell cycle block and growth inhibition by vinblastine in multidrug resistant human breast cancer cells. Baker WJ; Maenpaa JU; Wurz GT; Koester SK; Seymour RC; Emshoff VD; Wiebe VJ; DeGregorio MW Oncol Res; 1993; 5(6-7):207-12. PubMed ID: 8123940 [TBL] [Abstract][Full Text] [Related]
2. Monitoring the chemosensitizing effects of toremifene with flow cytometry in estrogen receptor negative multidrug resistant human breast cancer cells. Baker WJ; Wiebe VJ; Koester SK; Emshoff VD; Maenpaa JU; Wurz GT; DeGregorio MW Breast Cancer Res Treat; 1992; 24(1):43-9. PubMed ID: 1463871 [TBL] [Abstract][Full Text] [Related]
3. [Toremifene sensitized the effect of adriamycin on human breast cancer cell lines]. Nakagomi H; Furuya K; Hagiwara J; Nishio T; Watanabe K; Muto S; Takano K; Tada Y Gan To Kagaku Ryoho; 1998 Apr; 25 Suppl 3():454-8. PubMed ID: 9589052 [TBL] [Abstract][Full Text] [Related]
4. Effects of toremifene and its main metabolites on growth of breast cancer cell lines. Coradini D; Biffi A; Cappelletti V; Di Fronzo G Anticancer Res; 1991; 11(6):2191-7. PubMed ID: 1837981 [TBL] [Abstract][Full Text] [Related]
5. [Combined effects of toremifene and paclitaxel on human breast cancer cell lines]. Maruyama S; Kuroiwa S; Saimoto A; Nishikawa K Gan To Kagaku Ryoho; 2003 May; 30(5):669-75. PubMed ID: 12795099 [TBL] [Abstract][Full Text] [Related]
6. Flow cytometry: potential utility in monitoring drug effects in breast cancer. Koester SK; Maenpaa JU; Wiebe VJ; Baker WJ; Wurz GT; Seymour RC; Koehler RE; DeGregorio MW Breast Cancer Res Treat; 1994; 32(1):57-65. PubMed ID: 7819587 [TBL] [Abstract][Full Text] [Related]
7. [The in vitro combination-effect of toremifene with CAF (cyclophosphamide, adriamycin, 5-fluorouracil) on growth of various human mammary carcinomas]. Kuroiwa S; Maruyama S; Okada M; Abe F Gan To Kagaku Ryoho; 1998 Aug; 25(10):1581-9. PubMed ID: 9725052 [TBL] [Abstract][Full Text] [Related]
8. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Schwartz GK; Farsi K; Maslak P; Kelsen DP; Spriggs D Clin Cancer Res; 1997 Sep; 3(9):1467-72. PubMed ID: 9815832 [TBL] [Abstract][Full Text] [Related]
9. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites. Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885 [TBL] [Abstract][Full Text] [Related]
10. [Synergistic effect of toremifene and cisplatin on human lung cancer cell line A549]. Zhang X; Li Q; Han Y; Liu Z Zhonghua Zhong Liu Za Zhi; 2002 Nov; 24(6):537-9. PubMed ID: 12667319 [TBL] [Abstract][Full Text] [Related]
11. Coenzyme Q0 induces apoptosis and modulates the cell cycle in estrogen receptor negative breast cancer cells. Somers-Edgar TJ; Rosengren RJ Anticancer Drugs; 2009 Jan; 20(1):33-40. PubMed ID: 18830129 [TBL] [Abstract][Full Text] [Related]
12. Growth factors and chemotherapeutic modulation of breast cancer cells. Ciftci K; Su J; Trovitch PB J Pharm Pharmacol; 2003 Aug; 55(8):1135-41. PubMed ID: 12956904 [TBL] [Abstract][Full Text] [Related]
13. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells. McGuire KP; Ngoubilly N; Neavyn M; Lanza-Jacoby S J Surg Res; 2006 May; 132(2):208-13. PubMed ID: 16580691 [TBL] [Abstract][Full Text] [Related]
14. Effects of genistein and structurally related phytoestrogens on cell cycle kinetics and apoptosis in MDA-MB-468 human breast cancer cells. Balabhadrapathruni S; Thomas TJ; Yurkow EJ; Amenta PS; Thomas T Oncol Rep; 2000; 7(1):3-12. PubMed ID: 10601582 [TBL] [Abstract][Full Text] [Related]
15. Toremifene and its metabolites enhance doxorubicin accumulation in estrogen receptor negative multidrug resistant human breast cancer cells. Wiebe V; Koester S; Lindberg M; Emshoff V; Baker J; Wurz G; DeGregorio M Invest New Drugs; 1992 Jul; 10(2):63-71. PubMed ID: 1386843 [TBL] [Abstract][Full Text] [Related]
16. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer. Han GZ; Liu ZJ; Shimoi K; Zhu BT Cancer Res; 2005 Jan; 65(2):387-93. PubMed ID: 15695378 [TBL] [Abstract][Full Text] [Related]
17. Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells. Yin F; Giuliano AE; Law RE; Van Herle AJ Anticancer Res; 2001; 21(1A):413-20. PubMed ID: 11299771 [TBL] [Abstract][Full Text] [Related]
18. HIV-1 Tat peptide immunoconjugates differentially sensitize breast cancer cells to selected antiproliferative agents that induce the cyclin-dependent kinase inhibitor p21WAF-1/CIP-1. Hu M; Wang J; Chen P; Reilly RM Bioconjug Chem; 2006; 17(5):1280-7. PubMed ID: 16984139 [TBL] [Abstract][Full Text] [Related]
19. Effects of tamoxifen and the derivative (TAT) on cell cycle of MCF-7 in vitro. Tominaga T; Yoshida Y; Matsumoto A; Hayashi K; Kosaki G Anticancer Res; 1993; 13(3):661-5. PubMed ID: 8317894 [TBL] [Abstract][Full Text] [Related]
20. Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells. Foroodi F; Duivenvoorden WC; Singh G Anticancer Drugs; 2009 Feb; 20(2):115-22. PubMed ID: 19209028 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]